http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Genentech to Present New Data at AAN Highlighting Extensive Research for OCREVUS and Expanding Neuroscience Pipeline
-
GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment
-
Genentech to Present New Data Across a Range of Blood Diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
-
New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis
-
Genentech to Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data in Relapsing and Primary Progressive Forms of Multiple Sclerosis at ECTRIMS
-
Genentech (RHHBY) Says New Data at EAN Shows Ocrevus Reduced Disease Progression in RMS and PPMS
-
New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
-
Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
-
New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
-
Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis
-
Genentech Showcases New Clinical Data across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
-
Genentech (RHHBY) Plans Presentation of New Actemra, Rituxan Data at 2016 ACR/ARHP Annual Meeting
-
Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
-
Roche's (RHHBY) Genentech Announces New Data from OCREVUS Phase 3 in MS
-
Phase III Efficacy Results of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced by Exploratory Analyses in Two Forms of Multiple Sclerosis
-
Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparators on Disease Activity and Progression in Two Forms of Multiple Sclerosis
-
Genentech to Present New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2015 Annual Meeting
-
Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis
-
Genentech to Present Data from 15 Medicines Across Its Portfolio of Cancer Immunotherapy and Targeted Medicines During the 2015 European Cancer Congress
-
Pivotal Data for Genentech Medicines in Lung and Blood Cancers to Be Presented at ASCO
-
Trading Radar for 07/29: Pfizer (PFE), Marriott (MAR), UPS (UPS), Anadarko (APC), Ballard Power (BLDP) Report
-
Pre-Open Stock Movers 7/18: (ICLD) (GTIV) (SWKS) (GOOG) Higher; (RP) (NQ) (AMD) Lower (more...)
-
After-Hours Stock Movers 7/17: (SWSK) (GOOG) (AVGO) Higher; (AMD) (STX) (IBM) Lower (more...)
-
Trading Radar for 04/29: eBay (EBAY), Twitter (TWTR), Nokia (NOK), Express Scripts (ESRX), Seagate (STX) Report

